- Report
- January 2022
- 419 Pages
Global
From €9185EUR$9,500USD£7,889GBP
- Report
- April 2020
- 125 Pages
Global
From €3538EUR$3,660USD£3,039GBP
- Report
- April 2023
- 156 Pages
Global
€4834EUR$5,000USD£4,152GBP
- Report
- April 2023
- 114 Pages
Global
€3384EUR$3,500USD£2,906GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£830GBP
- Report
- July 2018
- 20 Pages
Global
From €9668EUR$10,000USD£8,304GBP
Anoro is a brand of respiratory drugs used to treat chronic obstructive pulmonary disease (COPD). It is a combination of two drugs, umeclidinium and vilanterol, which work together to relax the airways and reduce inflammation. Anoro is taken as an inhaler and is used to reduce symptoms such as shortness of breath, wheezing, and coughing. It is also used to prevent flare-ups of COPD.
Anoro is part of a larger market of respiratory drugs, which includes other brands such as Breo, Spiriva, and Symbicort. These drugs are used to treat a variety of respiratory conditions, including asthma, COPD, and bronchitis. They are available in both inhaler and pill form, and are often prescribed in combination with other medications.
The companies in the Anoro market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Novartis. Show Less Read more